Pembrolizumab

{
  "id": "MLC-T-ONC-006469",
  "term": "Pembrolizumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that express the protein PD-L1, that have certain mutations (changes) in genes involved in DNA repair, or that have a high number of tumor mutations. Pembrolizumab is used alone or with other drugs to treat certain types of biliary tract cancer (including bile duct cancer and gallbladder cancer), breast cancer, cervical cancer, classic Hodgkin lymphoma, colorectal cancer, endometrial cancer, esophageal cancer, gastroesophageal junction cancer, head and neck squamous cell carcinoma (SCC), hepatocellular carcinoma (a type of liver cancer), malignant pleural mesothelioma, non-small cell lung cancer, primary mediastinal large B-cell lymphoma, renal cell carcinoma (a type of kidney cancer), skin cancer (SCC of the skin, Merkel cell carcinoma, and melanoma), stomach cancer, urothelial carcinoma (a type of bladder or urinary tract cancer), and other solid tumors. It is also being studied in the treatment of other types of cancer. Pembrolizumab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Keytruda.",
    "A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity."
  ],
  "synonyms": [
    "Keytruda",
    "pembrolizumab biosimilar RPH-075",
    "pembrolizumab biosimilar SB27",
    "anti-PD-1 monoclonal antibody MK-3475",
    "immunoglobulin G4, anti-(human programmed cell death 1)",
    "humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide",
    "pembrolizumab biosimilar MB12",
    "pembrolizumab biosimilar BCD-201",
    "pembrolizumab biosimilar Q",
    "pembrolizumab biosimilar QL2107"
  ],
  "see_also": [
    "immune checkpoint inhibitor"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pembrolizumab/"
}